Cord Blood Stem Cells Information - Hematopoietic Stem Cells News

Hematopoietic Stem Cells News

DOR BioPharma Forms orBec® European Medical Advisory Board Friday, September 19, 2008 @ 6:03AMDOR BioPharma, Inc. announced recently the formation of a European Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it relates to the ongoing development of orBec for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD).
International Science Linkages announced Thursday, September 18, 2008 @ 12:21AMSydney University has been successful in securing a significant proportion of the federal funding for new international research projects announced this week.
Subscribe to the Daily Headlines E-mail Wednesday, September 3, 2008 @ 4:41AMNearly 15 years ago, scientists completed one of the largest international projects in research history, tremendous in its scope and importance. They determined the sequence of the nearly 30,000 genes in the human genome.
ImmuneRegen(R) BioSciences Confirms Homspera(R) Advances Wound Healing In Topical Application Monday, August 18, 2008 @ 7:15AMImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug candidate, Homspera®, has accelerated the healing process of deep, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc.
ImmuneRegen(R) BioSciences Confirms Homspera(R) Advances Wound Healing in Topical Application Wednesday, August 13, 2008 @ 5:53AMImmuneRegen(R) BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug candidate, Homspera(R), has accelerated the healing process of deep, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc., a biotechnology development company that also ...
ImmuneRegen(R) BioSciences Confirms Homspera(R) Advances Wound Healing in Topical Application Wednesday, August 13, 2008 @ 5:30AM SCOTTSDALE, Ariz.----ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. , today announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug candidate, Homspera®, has accelerated the healing process of deep, dermal excisions.
Protein Key to Control Growth of Blood Cells Tuesday, August 5, 2008 @ 10:24AM --Findings May Aid in Bone Marrow Transplants, Blood Diseases--
Process By Which All Blood Cells Originate Is Essentially The Same Throughout Mammal World Monday, August 4, 2008 @ 1:23PMThe architecture of haematopoiesis – which is the process by which all blood cells originate – is essentially the same throughout the mammal world, report scientists in the Proceedings of the Royal Society. This is an unexpected result considering the thousands of mammals’ species with a myriad of habitats and lifestyles, as so well demonstrated when comparing the 30 mm flying bumblebee bat and ...
Identification Of Protein Able To Stimulate Production Of T-Cells Thursday, July 24, 2008 @ 3:10AMA team of Canadian and Finnish scientists has identified a protein able to stimulate the production of T-cells, the white blood cells involved in the recognition and the elimination of infectious agents.
Dynamics Of Hematopoiesis Across Mammals Wednesday, July 16, 2008 @ 3:17AMHematopoiesis is the process responsible for blood cell formation. At the root of this process lie hematopoietic stem cells. The demands for hematopoietic output vary across mammals, where the number of active hematopoietic stem cells scales with mass. Hematopoietic stem cells can be linked with the circulating blood with a model based on human data.
Method for activating natural killer cells by tumor cell preparation in vitro Wednesday, July 16, 2008 @ 2:05AMThe present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumour cell preparation (ATCP). The invention
Muscle Stem Cell Transplant Boosts Diseased Muscle Function and Replenishes Stem Cell Pool Thursday, July 10, 2008 @ 11:25AMResearchers at the Joslin Diabetes Center have demonstrated for the first time that transplanted muscle stem cells can both improve muscle function in animals with a form of muscular dystrophy and replenish the stem cell population for use in the repair of future muscle injuries.
Donor sex may influence transplant success Wednesday, July 9, 2008 @ 6:50AMThe results of a Swiss-led study on the long-term success of kidney transplants suggest that organs should be distributed to recipients of the same sex as the donor.
St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease Monday, July 7, 2008 @ 11:00AM A ubiquitous housekeeping enzyme has been found to play a major role in keeping the bone marrow environment healthy so it can nurture hematopoietic stem cells
Pluristem Certified as a Good Manufacturing Practices (GMP) Site for the Manufacture of PLX cells for its Clinical ... Wednesday, June 25, 2008 @ 9:00AM NEW YORK----Pluristem Therapeutics Inc. ; , a bio-therapeutics company dedicated to the commercialization of non-personalized cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company has received certification that its manufacturing facility in Haifa, Israel has been approved as a Good Manufacturing Practices standard site for ...
Myasthenia gravis transplant Wednesday, June 18, 2008 @ 9:39AMBy Jen Christensen Posted: Wednesday, June 18, 2008 at 9:32 a.m. Myasthenia Gravis Myasthenia gravis (MG) is an autoimmune condition that affects the muscles. The muscles are controlled by nerve impulses, or electrical signals sent from the brain.
Clinical Data For REVLIMID(R) And VIDAZA(R) In Important Blood Cancers Presented at The 13th European Hematology ... Tuesday, June 17, 2008 @ 6:46AMCelgene International Sarl (Nasdaq: CELG):
Clinical Data For REVLIMID(R) And VIDAZA(R) In Important Blood Cancers Presented at The 13th European Hematology ... Tuesday, June 17, 2008 @ 6:30AM BOUDRY, Switzerland----Celgene International Sarl : Study of VIDAZA in Higher-Risk MDS Patients Reports Improved Overall Survival New Analysis of Phase III Studies Shows REVLIMID Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple Myeloma Health Economic Analysis Reports that REVLIMID is a Cost Effective Treatment for Multiple Myeloma Preliminary ...
Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research ... Monday, June 16, 2008 @ 7:35AMOpexa Therapeutics, Inc. (NASDAQ: OPXA), a cell therapy development and commercialization company, today announced a recent poster presentation at the 2008 Annual Meeting of the International Society for Stem Cell Research held in Philadelphia June 11 - 14, 2008. The poster, titled "Ex vivo differentiation of adult human peripheral blood monocyte-derived cells into functional insulin-producing ...
Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research ... Monday, June 16, 2008 @ 7:00AM THE WOODLANDS, Texas----Opexa Therapeutics, Inc. , a cell therapy development and commercialization company, today announced a recent poster presentation at the 2008 Annual Meeting of the International Society for Stem Cell Research held in Philadelphia June 11 - 14, 2008.
ImmuneRegen(R) BioSciences Confirms Adult Stem Cell Activity of Homspera(R) in Human Bone Marrow Monday, June 9, 2008 @ 5:30AM SCOTTSDALE, Ariz.----ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. , announces additional study results that confirm the effects of its compound Homspera® in stimulating the development of human adult stem cells.
Gentium Announces Update from Data Safety Monitoring Board Review of the Phase III Treatment Trial of Defibrotide for ... Thursday, June 5, 2008 @ 3:10PMGentium S.p.A (5870;NASDAQ:GENT) announced today that an independent Data Safety Monitoring Board (DSMB)
Washington DC Thursday, June 5, 2008 @ 7:42AMSAN DIEGO , June 5 /PRNewswire-FirstCall/ -- In an editorial commentary(1) in the current issue of The Journal of Infectious Diseases (JID), independent experts on cytomegalovirus (CMV) said the vaccine under development by Vical Incorporated (Nasdaq: VICL ), at the optimal dose and regimen tested, "holds promise" based on its ability to elicit persistent immune responses in a majority of ...
Education News Tuesday, June 3, 2008 @ 7:47AMClarion University named its 11 outstanding graduate students during the seventh annual Graduate Student Research and Professional Activities Conference in the Carlson Library.
San Francisco Monday, June 2, 2008 @ 9:35AMEXTON, Pa. ( Map ) - EXTON, Pa. , June 2 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced the publication of results of its previously described Phase 2 study showing that maribavir, when used as prophylaxis, reduced the rate of cytomegalovirus (CMV) reactivation and was well tolerated when compared to placebo in allogeneic stem cell, or bone marrow, transplant ...
New Publication of Phase 2 Data Shows Maribavir Markedly Reduced the Rate of Cytomegalovirus Infection and Disease in ... Monday, June 2, 2008 @ 7:00AM ViroPharma Incorporated today announced the publication of results of its previously described Phase 2 study showing that maribavir, when used as prophylaxis, reduced the rate of cytomegalovirus reactivation and was well tolerated when compared to placebo in allogeneic stem cell, or bone marrow, transplant patients.
San Francisco Thursday, May 29, 2008 @ 8:20AMEXTON, Pa. ( Map ) - EXTON, Pa. , May 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal Phase 3 study of maribavir in stem cell transplant patients.
Genetic Changes May Dictate Course of Acute Myeloid Leukemia Thursday, May 1, 2008 @ 2:34PMTitle: Genetic Changes May Dictate Course of Acute Myeloid Leukemia Category: Health News Created: 5/1/2008 2:00:00 AM Last Editorial Review: 5/1/2008
Genetic Changes May Dictate Course of Acute Myeloid Leukemia Wednesday, April 30, 2008 @ 10:17PM By Amanda Gardner , HealthDay Reporter WEDNESDAY, April 30 (HealthDay News) -- Breakthroughs in understanding the extremely fine genetic underpinnings of acute...
Genetic Changes May Dictate Course of Acute Myeloid Leukemia Wednesday, April 30, 2008 @ 4:02PM WEDNESDAY, April 30 (HealthDay News) -- Breakthroughs in understanding the extremely fine genetic underpinnings of acute myeloid leukemia may allow doctors to quickly decide which existing therapies will most benefit individual patients.
Oncolytics Biotech Inc. Announces 2008 First Quarter Results Wednesday, April 30, 2008 @ 3:30PM Oncolytics Biotech Inc. today announced its financial results and highlights for the three month period ended March 31, 2008.
New type of stem cells coaxed into heart tissue Wednesday, April 30, 2008 @ 3:11PMWASHINGTON (Reuters) - A new type of powerful stem cell made from ordinary skin cells has been coaxed into becoming three different types of heart and blood cells in mice, U.S. researchers reported on Wednesday.
Stem cells coaxed into heart tissue Wednesday, April 30, 2008 @ 2:50PMA NEW type of powerful stem cell made from ordinary skin cells has been coaxed into becoming three different types of heart and blood cells in mice, US researchers reported today.